Present at the Revolution: Transformation of Technical Identity for a Large Incumbent Pharmaceutical Firm After the Biotechnological Breakthrough
Author
Abstract
Suggested Citation
Note: PR
Download full text from publisher
References listed on IDEAS
- Elise Brezis & Paul Krugman & Daniel Tsiddon, 1991. "Leapfrogging: A Theory of Cycles in National Technological Leadership," NBER Working Papers 3886, National Bureau of Economic Research, Inc.
- Henry Grabowski & John Vernon, 1990. "A New Look at the Returns and Risks to Pharmaceutical R&D," Management Science, INFORMS, vol. 36(7), pages 804-821, July.
- Reinganum, Jennifer F, 1983.
"Uncertain Innovation and the Persistence of Monopoly,"
American Economic Review, American Economic Association, vol. 73(4), pages 741-748, September.
- Reinganum, Jennifer R., 1982. "Uncertain Innovation and the Persistence of Monopoly," Working Papers 431, California Institute of Technology, Division of the Humanities and Social Sciences.
- Gary P. Pisano, 1994. "Knowledge, Integration, and the Locus of Learning: An Empirical Analysis of Process Development," Strategic Management Journal, Wiley Blackwell, vol. 15(S1), pages 85-100, December.
- Lynne G. Zucker & Michael R. Darby & Jeff Armstrong, 1994. "Intellectual Capital and the Firm: The Technology of Geographically Localized Knowledge Spillovers," NBER Working Papers 4946, National Bureau of Economic Research, Inc.
- Reinganum, Jennifer F., 1989. "The timing of innovation: Research, development, and diffusion," Handbook of Industrial Organization, in: R. Schmalensee & R. Willig (ed.), Handbook of Industrial Organization, edition 1, volume 1, chapter 14, pages 849-908, Elsevier.
- Grabowski, Henry G. & Vernon, John M., 1994. "Returns to R&D on new drug introductions in the 1980s," Journal of Health Economics, Elsevier, vol. 13(4), pages 383-406.
- Wooldridge, Jeffrey M., 1991. "On the application of robust, regression- based diagnostics to models of conditional means and conditional variances," Journal of Econometrics, Elsevier, vol. 47(1), pages 5-46, January.
- Comanor, William S, 1986. "The Political Economy of the Pharmaceutical Industry," Journal of Economic Literature, American Economic Association, vol. 24(3), pages 1178-1217, September.
- Zucker, Lynne G. & Darby, Michael R., 1994. "The Organization of Biotechnology Science and Its Commercialization in Japan," Institute for Social Science Research, Working Paper Series qt9qf459t4, Institute for Social Science Research, UCLA.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Lynne G. Zucker & Michael R. Darby, 1996. "Costly Information in Firm Transformation, Exit, or Persistent Failure," NBER Working Papers 5577, National Bureau of Economic Research, Inc.
- Mangematin, V., 2000. "PhD job market: professional trajectories and incentives during the PhD," Research Policy, Elsevier, vol. 29(6), pages 741-756, June.
- Luigi Orsenigo & Fabio Pammolli & Massimo Riccaboni & Andrea Bonaccorsi & Giuseppe Turchetti, 1997. "The Evolution of Knowledge and the Dynamics of an Industry Network," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 1(2), pages 147-175, June.
- Nicola Lacetera, 2000. "Corporate Governance and the Governance of Innovation: the Case of Pharmaceutical Industry," KITeS Working Papers 122, KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, revised Dec 2000.
- Nicola Lacetera, 2001. "Corporate Governance and the Governance of Innovation: The Case of Pharmaceutical Industry," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 5(1), pages 29-59, March.
- Jorge Niosi & Maureen McKelvey, 2018. "Relating business model innovations and innovation cascades: the case of biotechnology," Journal of Evolutionary Economics, Springer, vol. 28(5), pages 1081-1109, December.
- Iain Cockburn & Rebecca Henderson & Scott Stern, 1999. "The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research," NBER Working Papers 7359, National Bureau of Economic Research, Inc.
- Hicks, Diana & Breitzman, Tony & Olivastro, Dominic & Hamilton, Kimberly, 2001. "The changing composition of innovative activity in the US -- a portrait based on patent analysis," Research Policy, Elsevier, vol. 30(4), pages 681-703, April.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Zucker, Lynne G. & Darby, Michael R., 1997. "Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm," Research Policy, Elsevier, vol. 26(4-5), pages 429-446, December.
- Michael R. Darby & Lynne G. Zucker, 1996. "Star Scientists, Institutions, and the Entry of Japanese Biotechnology Enterprises," NBER Working Papers 5795, National Bureau of Economic Research, Inc.
- McGahan, Anita M. & Silverman, Brian S., 2006. "Profiting from technological innovation by others: The effect of competitor patenting on firm value," Research Policy, Elsevier, vol. 35(8), pages 1222-1242, October.
- Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
- Schwartz, Eduardo S., 2002. "Patents and R& D as Real Options," University of California at Los Angeles, Anderson Graduate School of Management qt86b1n43k, Anderson Graduate School of Management, UCLA.
- Joseph P. Cook & Joseph Golec, 2017. "How excluding some benefits from value assessment of new drugs impacts innovation," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1813-1825, December.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Robert J. Barro & Xavier Sala-i-Martin, 1994.
"Quality Improvements in Models of Growth,"
NBER Working Papers
4610, National Bureau of Economic Research, Inc.
- Barro, Robert J. & Sala-i-Martin, Xavier, 1994. "Quality Improvements in Models of Growth," CEPR Discussion Papers 1076, C.E.P.R. Discussion Papers.
- Sala-i-Martin, X. & Barro, R.J., 1994. "Quality Improvements in Models of Growth," Papers 715, Yale - Economic Growth Center.
- Robert J. Barro & Xavier Sala-i-Martin, 1994. "Quality improvements in models of growth," Economics Working Papers 84, Department of Economics and Business, Universitat Pompeu Fabra.
- Ming Ding & Jehoshua Eliashberg, 2002. "Structuring the New Product Development Pipeline," Management Science, INFORMS, vol. 48(3), pages 343-363, March.
- Leibowicz, Benjamin D., 2018. "Welfare improvement windows for innovation policy," Research Policy, Elsevier, vol. 47(2), pages 390-398.
- Joseph Dimasi & Henry Grabowski & John Vernon, 1995.
"R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry,"
International Journal of the Economics of Business, Taylor & Francis Journals, vol. 2(2), pages 201-219.
- Joseph A. Dimasi & Grabowski, Henry G. & Vernon, John, 1995. "R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry," Working Papers 95-16, Duke University, Department of Economics.
- Tapon, Francis & Cadsby, Charles Bram, 1996. "The optimal organization of research: evidence from eight case studies of pharmaceutical firms," Journal of Economic Behavior & Organization, Elsevier, vol. 31(3), pages 381-399, December.
- Austin, David H., 2000.
"Patents, Spillovers, and Competition in Biotechnology,"
Discussion Papers
10808, Resources for the Future.
- Austin, David, 2000. "Patents, Spillovers and Competition in Biotechnology," RFF Working Paper Series dp-00-53, Resources for the Future.
- Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
- Karel Cool & Ingemar Dierickx, 1993. "Abstract," Strategic Management Journal, Wiley Blackwell, vol. 14(1), pages 47-59, January.
- Casper, Steven & Matraves, Catherine, 2003. "Institutional frameworks and innovation in the German and UK pharmaceutical industry," Research Policy, Elsevier, vol. 32(10), pages 1865-1879, December.
- Hoppe, Heidrun C., 2000. "Second-mover advantages in the strategic adoption of new technology under uncertainty," International Journal of Industrial Organization, Elsevier, vol. 18(2), pages 315-338, February.
- Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
- Aldieri, Luigi & Aprile, Maria Carmela & Vinci, Concetto Paolo, 2015. "R&D Spillovers Effects on strategic behaviour of Large International Firms," MPRA Paper 63402, University Library of Munich, Germany.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberwo:5243. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.